Serum thyrotropin-binding inhibiting immunoglobulin and thyroperoxidase antibody in Graves' hyperthyroidism after 131I therapy

C. H. Hsu, L. S. Lee, J. J. Chang, S. T. Liao, S. M. Chen, J. Y. Hwang, N. I. Lo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Seventeen patients who received radioiodine (131I) therapy for Graves' hyperthyroidism had serial blood samples taken before therapy and after therapy for a period of at least 1 year. At 1 year post-therapy, six patients were hypothyroid. Seven patients were euthyroid, and four patients were hyperthyroid. Prior to isotope administration, 14 patients had detectable serum thyrotropin-binding inhibiting immunoglobulin (TBII) and 16 patients had detectable serum thyroperoxidase antibody (TPOAb). Three to 6 months after therapy, 11 of 14 TBII-positive patients demonstrated a marked increase (> 10%) in serum TBII activity. Four patients out of 11 developed hypothyroidism and six of the 11 developed euthyroidism. A decrease in TBII was observed in three patients who developed hyperthyroidism. In the three patients with undetectable TBII prior to therapy, two had high titers of TPOAb. Seven patients demonstrated a marked increase in TPOAb 3 to 6 months after therapy. Of these, four developed hypothyroidism and three developed euthyroidism, whereas three of the four patients who had a marked decrease in TPOAb developed hyperthyroidism. This study demonstrated that an increase in serum TBII and TPOAb activity 3 to 6 months after 131I therapy, may be useful in predicting which patients may develop euthyroidism or hypothyroidism after 1 year of 131 therapy.

Original languageEnglish
Pages (from-to)5-9
Number of pages5
JournalJournal of the Formosan Medical Association
Volume94
Issue number1-2
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Thyrotropin
Hyperthyroidism
Immunoglobulins
Antibodies
Serum
Therapeutics
Hypothyroidism
Isotopes

Keywords

  • Graves' disease
  • immunoglobulin
  • radioiodine therapy
  • thyroperoxidase antibody
  • thyrotropin-binding inhibiting

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Serum thyrotropin-binding inhibiting immunoglobulin and thyroperoxidase antibody in Graves' hyperthyroidism after 131I therapy. / Hsu, C. H.; Lee, L. S.; Chang, J. J.; Liao, S. T.; Chen, S. M.; Hwang, J. Y.; Lo, N. I.

In: Journal of the Formosan Medical Association, Vol. 94, No. 1-2, 1995, p. 5-9.

Research output: Contribution to journalArticle

Hsu, C. H. ; Lee, L. S. ; Chang, J. J. ; Liao, S. T. ; Chen, S. M. ; Hwang, J. Y. ; Lo, N. I. / Serum thyrotropin-binding inhibiting immunoglobulin and thyroperoxidase antibody in Graves' hyperthyroidism after 131I therapy. In: Journal of the Formosan Medical Association. 1995 ; Vol. 94, No. 1-2. pp. 5-9.
@article{db52d4b7f15f4cf79a1dd032e2b8e644,
title = "Serum thyrotropin-binding inhibiting immunoglobulin and thyroperoxidase antibody in Graves' hyperthyroidism after 131I therapy",
abstract = "Seventeen patients who received radioiodine (131I) therapy for Graves' hyperthyroidism had serial blood samples taken before therapy and after therapy for a period of at least 1 year. At 1 year post-therapy, six patients were hypothyroid. Seven patients were euthyroid, and four patients were hyperthyroid. Prior to isotope administration, 14 patients had detectable serum thyrotropin-binding inhibiting immunoglobulin (TBII) and 16 patients had detectable serum thyroperoxidase antibody (TPOAb). Three to 6 months after therapy, 11 of 14 TBII-positive patients demonstrated a marked increase (> 10{\%}) in serum TBII activity. Four patients out of 11 developed hypothyroidism and six of the 11 developed euthyroidism. A decrease in TBII was observed in three patients who developed hyperthyroidism. In the three patients with undetectable TBII prior to therapy, two had high titers of TPOAb. Seven patients demonstrated a marked increase in TPOAb 3 to 6 months after therapy. Of these, four developed hypothyroidism and three developed euthyroidism, whereas three of the four patients who had a marked decrease in TPOAb developed hyperthyroidism. This study demonstrated that an increase in serum TBII and TPOAb activity 3 to 6 months after 131I therapy, may be useful in predicting which patients may develop euthyroidism or hypothyroidism after 1 year of 131 therapy.",
keywords = "Graves' disease, immunoglobulin, radioiodine therapy, thyroperoxidase antibody, thyrotropin-binding inhibiting",
author = "Hsu, {C. H.} and Lee, {L. S.} and Chang, {J. J.} and Liao, {S. T.} and Chen, {S. M.} and Hwang, {J. Y.} and Lo, {N. I.}",
year = "1995",
language = "English",
volume = "94",
pages = "5--9",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "1-2",

}

TY - JOUR

T1 - Serum thyrotropin-binding inhibiting immunoglobulin and thyroperoxidase antibody in Graves' hyperthyroidism after 131I therapy

AU - Hsu, C. H.

AU - Lee, L. S.

AU - Chang, J. J.

AU - Liao, S. T.

AU - Chen, S. M.

AU - Hwang, J. Y.

AU - Lo, N. I.

PY - 1995

Y1 - 1995

N2 - Seventeen patients who received radioiodine (131I) therapy for Graves' hyperthyroidism had serial blood samples taken before therapy and after therapy for a period of at least 1 year. At 1 year post-therapy, six patients were hypothyroid. Seven patients were euthyroid, and four patients were hyperthyroid. Prior to isotope administration, 14 patients had detectable serum thyrotropin-binding inhibiting immunoglobulin (TBII) and 16 patients had detectable serum thyroperoxidase antibody (TPOAb). Three to 6 months after therapy, 11 of 14 TBII-positive patients demonstrated a marked increase (> 10%) in serum TBII activity. Four patients out of 11 developed hypothyroidism and six of the 11 developed euthyroidism. A decrease in TBII was observed in three patients who developed hyperthyroidism. In the three patients with undetectable TBII prior to therapy, two had high titers of TPOAb. Seven patients demonstrated a marked increase in TPOAb 3 to 6 months after therapy. Of these, four developed hypothyroidism and three developed euthyroidism, whereas three of the four patients who had a marked decrease in TPOAb developed hyperthyroidism. This study demonstrated that an increase in serum TBII and TPOAb activity 3 to 6 months after 131I therapy, may be useful in predicting which patients may develop euthyroidism or hypothyroidism after 1 year of 131 therapy.

AB - Seventeen patients who received radioiodine (131I) therapy for Graves' hyperthyroidism had serial blood samples taken before therapy and after therapy for a period of at least 1 year. At 1 year post-therapy, six patients were hypothyroid. Seven patients were euthyroid, and four patients were hyperthyroid. Prior to isotope administration, 14 patients had detectable serum thyrotropin-binding inhibiting immunoglobulin (TBII) and 16 patients had detectable serum thyroperoxidase antibody (TPOAb). Three to 6 months after therapy, 11 of 14 TBII-positive patients demonstrated a marked increase (> 10%) in serum TBII activity. Four patients out of 11 developed hypothyroidism and six of the 11 developed euthyroidism. A decrease in TBII was observed in three patients who developed hyperthyroidism. In the three patients with undetectable TBII prior to therapy, two had high titers of TPOAb. Seven patients demonstrated a marked increase in TPOAb 3 to 6 months after therapy. Of these, four developed hypothyroidism and three developed euthyroidism, whereas three of the four patients who had a marked decrease in TPOAb developed hyperthyroidism. This study demonstrated that an increase in serum TBII and TPOAb activity 3 to 6 months after 131I therapy, may be useful in predicting which patients may develop euthyroidism or hypothyroidism after 1 year of 131 therapy.

KW - Graves' disease

KW - immunoglobulin

KW - radioiodine therapy

KW - thyroperoxidase antibody

KW - thyrotropin-binding inhibiting

UR - http://www.scopus.com/inward/record.url?scp=0029036030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029036030&partnerID=8YFLogxK

M3 - Article

VL - 94

SP - 5

EP - 9

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 1-2

ER -